Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Neurology | Oncology

Brain Metastases Clinical Trials

A listing of Brain Metastases medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

Filter by:

Phase:

Gender:

Age:

Location:

 

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic email notifications as soon as a clinical trial is posted in the medical category you're interested in.


Alabama

University of Alabama at Birmingham
Birmingham Alabama 35249

A Phase 2 clinical study for patients with Brain Metastases or Non-small Cell Lung Cancer

University Of Alabama at Birmingham
Birmingham Alabama 35294
Updated

A Phase 2 clinical study for patients with HER-2 Positive Breast Cancer

Maryland

NCI
Rockville Maryland 20892

Patients are needed to participate in a clinical research study of GRN1005 and Trastuzumab to evaluate Breast Cancer or Brain Metastases

Massachusetts

Beth Israel Deaconess Medical Center
Boston Massachusetts 02115

A Phase 2 clinical study for patients with Brain Metastases or Solid Tumors

Dana-Farber Cancer Institute
Boston Massachusetts 02115

A Phase 2 clinical study for patients with Brain Metastases or Solid Tumors

New Jersey

Memoral Sloan Kettering Cancer Center
Basking Ridge New Jersey

Patients are needed to participate in a clinical research study evaluating Whole Brain Radiotherapy (WBRT) and Sorafenib for the treatment of Breast Cancer or Brain Metastases

New York

Memorial Sloan-Kettering Cancer Center @ Suffolk
Commack New York 11725

Patients are needed to participate in a clinical research study evaluating Whole Brain Radiotherapy (WBRT) and Sorafenib for the treatment of Breast Cancer or Brain Metastases

Department of Radiation oncology, Memorial Sloan Kettering Cancer Center
New York New York 10065

A Phase 2 clinical study for patients with Brain Metastases or Solid Tumors

Memorial Sloan Kettering Cancer Center
New York New York 10065

Patients are needed to participate in a clinical research study evaluating Whole Brain Radiotherapy (WBRT) and Sorafenib for the treatment of Breast Cancer or Brain Metastases

Memorial Sloan-Kettering at Mercy Medical Center
Rockville Centre New York

Patients are needed to participate in a clinical research study evaluating Whole Brain Radiotherapy (WBRT) and Sorafenib for the treatment of Breast Cancer or Brain Metastases

Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital
Sleepy Hollow New York

Patients are needed to participate in a clinical research study evaluating Whole Brain Radiotherapy (WBRT) and Sorafenib for the treatment of Breast Cancer or Brain Metastases

North Carolina

UNC Lineberger Comprehensive Cancer Center
Chapel Hill North Carolina 27599
Updated

A Phase 2 clinical study for patients with HER-2 Positive Breast Cancer

UNC Lineberger Comprehensive Cancer Center
Chapel Hill North Carolina 27599

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

Ohio

Gabrail Cancer Center Research
Canton Ohio 44718
Updated

A clinical research study of ANG1005 for the treatment of Breast Cancer or Brain Metastases

Pennsylvania

UPMC Shadyside Radiation Oncology
Pittsburgh Pennsylvania 15232

A Phase 2 clinical study for patients with Brain Metastases or Solid Tumors

Tennessee

Vanderbilt-Ingram Cancer Center
Nashville Tennessee 37212
Updated

A Phase 2 clinical study for patients with HER-2 Positive Breast Cancer

Texas

UT MD Anderson Cancer Center
Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating TPI 287, Dexamethasone, Benadryl and Ranitidine for the treatment of Breast Cancer

Austria

Medical University of Vienna
Vienna

A clinical trial to evaluate treatments using NovoTTF-100A device and Best Standard of Care for patients with 1-3 Brain Metastases From Non-Small Cell Lung Cancer

Belgium

Universitair Ziekenhuis Antwerpen
Antwerp B-2650

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

Jules Bordet Institute
Brussels B-1000

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

China

West China Hospital
Chengdu Sichuan 610041

A clinical research study of icotinib and Whole brain radiotherapy for the treatment of Non-small Cell Lung Cancer or Brain Metastases

The First People's Hospital of Lianyungang
Lianyungang Jiangsu 222002

Patients are needed to participate in a clinical research study of 6MV-X ray and Endostar to evaluate Brain Metastases

Czech Republic

Na Homolce Hospital
Prague

A clinical trial to evaluate treatments using NovoTTF-100A device and Best Standard of Care for patients with 1-3 Brain Metastases From Non-Small Cell Lung Cancer

France

Institut Curie
Paris Paris Cedex 05 75248

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

Institut Gustave Roussy
Villejuif Val de Marne 94805

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

Israel

Tel Aviv Sourasky Medical Center
Tel Aviv 64239

A clinical trial to evaluate treatments using NovoTTF-100A device and Best Standard of Care for patients with 1-3 Brain Metastases From Non-Small Cell Lung Cancer

Italy

Ospedale Lecco
Lecco

A clinical trial to evaluate treatments using NovoTTF-100A device and Best Standard of Care for patients with 1-3 Brain Metastases From Non-Small Cell Lung Cancer

Netherlands

Antoni van Leeuwenhoek Ziekenhuis
Amsterdam 1066 CX

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

Vrije Universiteit medisch centrum (Vumc)
Amsterdam 1081 HV

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

Leids Universitair Medisch Centrum (LUMC)
Leiden 2333 CA

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

Maastricht Universitair Medisch Centrum
Maastricht 6229 HX

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

Erasmus MC
Rotterdam 3075 EA

Patients are needed to participate in a clinical research study evaluating 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks and 2B3-101 50 mg/m2 every 3 weeks

Spain

Hospital 12 de Octubre
Madrid

A clinical trial to evaluate treatments using NovoTTF-100A device and Best Standard of Care for patients with 1-3 Brain Metastases From Non-Small Cell Lung Cancer

Clínica Universidad de Navarra
Pamplona
Updated

A clinical trial seeking patients for a research study for the treatment of Melanoma or Brain Metastases